Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy
dc.authorid | 0000-0003-4889-208X | en_US |
dc.authorid | 0000-0003-2157-0304 | en_US |
dc.authorid | 0000-0002-6054-9244 | en_US |
dc.authorid | 0000-0002-1979-9145 | en_US |
dc.contributor.author | Güzelbulut, Fatih | |
dc.contributor.author | Gökçen, Pınar | |
dc.contributor.author | Can, Güray | |
dc.contributor.author | Adalı, Gupse | |
dc.contributor.author | Saltürk, Ayça Gökçen Değirmenci | |
dc.date.accessioned | 2023-07-17T12:25:06Z | |
dc.date.available | 2023-07-17T12:25:06Z | |
dc.date.issued | 2021 | en_US |
dc.department | BAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.description.abstract | The HCC-RESCUE score was developed to predict hepatocellular carcinoma (HCC) risk in Korean chronic hepatitis B (CHB) patients under entecavir therapy. We aimed to validate the HCC-RESCUE score to predict HCC risk in Caucasian CHB patients under entecavir or tenofovir therapy and to compare the predictive performance of the HCC-RESCUE score with those of the CAMD, PAGE-B and modified PAGE-B (mPAGE-B) scores. The study included 647 nucleos(t)ide analogue-naive noncirrhotic and compensated/decompensated cirrhotic patients who had received entecavir or tenofovir for >= 6 months and did not develop HCC during the first 6 months of therapy. Patients with HCC-RESCUE scores <= 64, 65-84 and >= 85 points were classified into low-, intermediate- and high-risk groups, respectively. The AUROCs of the HCC-RESCUE, CAMD, PAGE-B and mPAGE-B scores to predict HCC risk at 5 years were 0.875, 0.870, 0.866 and 0.880, and those at 10 years were 0.862, 0.845, 0.841 and 0.862, respectively (both p > .05). Cumulative HCC incidences at 5 years were 0.0%, 10.5% and 15.8%, and those at 10 years were 1.4%, 15.5% and 24.9%, respectively, in the low-, intermediate- and high-risk groups based on the HCC-RESCUE score (both log rank p < .001). In the entecavir versus tenofovir cohorts, the AUROCs of the HCC-RESCUE score to predict HCC risk at 5 and 10 years were 0.831 versus 0.898 and 0.803 versus 0.910, respectively (both p > .05). The HCC-RESCUE score accurately predicted HCC risk in Caucasian CHB patients under entecavir or tenofovir therapy. A substantial proportion of patients can be dropped from HCC surveillance by using the HCC-RESCUE score. | en_US |
dc.identifier.citation | Güzelbulut, F., Gökçen, P., Can, G., Adalı, G., Değirmenci Saltürk, A. G., Bahadır, Ö., ... & Doğanay, H. L. (2021). Validation of the HCC‐RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy. Journal of Viral Hepatitis, 28(5), 826-836. | en_US |
dc.identifier.doi | 10.1111/jvh.13485 | |
dc.identifier.endpage | 836 | en_US |
dc.identifier.issn | 1352-0504 | |
dc.identifier.issn | 1365-2893 | |
dc.identifier.issue | 5 | en_US |
dc.identifier.pmid | 33586270 | en_US |
dc.identifier.scopus | 2-s2.0-85101935713 | en_US |
dc.identifier.scopusquality | Q2 | en_US |
dc.identifier.startpage | 826 | en_US |
dc.identifier.uri | http://dx.doi.org/10.1111/jvh.13485 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12491/11301 | |
dc.identifier.volume | 28 | en_US |
dc.identifier.wos | WOS:000621124200001 | en_US |
dc.identifier.wosquality | Q3 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.institutionauthor | Can, Güray | |
dc.language.iso | en | en_US |
dc.publisher | WILEY | en_US |
dc.relation.ispartof | Journal of Viral Hepatitis | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Chronic Hepatitis B | en_US |
dc.subject | Hepatocellular Carcinoma | en_US |
dc.subject | Risk Prediction | en_US |
dc.subject | HCC-RESCUE | en_US |
dc.title | Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy | en_US |
dc.type | Article | en_US |